TOKYO, Mar 29, 2024 – (JCN Newswire) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co…
Read More
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
![Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical](https://www.unifitrip.com/wp-content/uploads/2024/03/70296-eisai-to-divest-rights-for-merislon-and-myonal-in-japan-to-kaken-pharmaceutical.jpg)
Recent Comments